“we've highlighted that if you look at our next generation of our next wave of RINVOQ approvals, that we anticipate roughly $2 billion or more in peak year sales.”

In context

“omentum. The profile of both drugs is very powerful. And the commercial execution has been very strong. Elizabeth Shea: Thank you, Mohit. Operator, next question please. Operator: Next question is from David Amsellem with Piper Sandler. Your line is open. David Amsellem: Hey, thanks. So on RINVOQ and Vitiligo, can you talk about the sizing of that opportunity given the dirt that's systemic options? And also, do you perceive a competitive threat from IL-fifteen directed therapies in vitiligo down the road? That's number one. And then secondly, as you talk about potential replacement for Vraylar following its LOE, does that also contemplate a long-acting form of cariprazine as one of those replacements? Thanks. Jeffrey Stewart: Yeah. Hi. It's Jeff. I'll take the vitiligo question. So, yeah, we've highlighted that if you look at our next generation of our next wave of RINVOQ approvals, that we anticipate roughly $2 billion or more in peak year sales. And those are going to start to gate out here relatively soon. We're right on track with GCA, which is moving quite well. It's the smallest of the bunch. It's difficult to say. When we look at vitiligo, I mean, we've sized that opportunity, you know, roughly just above half a billion at peak. But, again, we could surprise ourselves there. I mean, the data looks quite strong. And to your point, it is the only systemic agent. And so, ultimately, where we end up in terms of that peak year sales will also depend on the labeling that we get as we go through the process. Certainly, we're reviewing quite a bit of disease state awareness that we'll start to gate in with AbbVie spending in the middle part of the year where we're gonna basically highlight the fact that there is no systemic treatmen”